CE-27
Mortality in
Controlled Studies
All cause mortality,
n/N
% (95% CI)
% (95% CI)
3/554
0.5% (0.1, 1.6)
4/749
0.5% (0.1, 1.4)
7/1737
0.4% (0.2, 0.8)
0.4% (0.2, 0.8)
Ranolazine
3/455
0.7% (0.1, 1.9)
0.7% (0.1, 1.9)
Phase 3 SR
Controlled studies
4/1266
0.3% (0.1, 0.8)
0.3% (0.1, 0.8)
Phase 2/3 IR + SR
Controlled studies
3/269
1.1% (0.1, 3.2)
CARISA
Placebo
Study population
Note: Exact binomial distribution
confidence intervals (CIs).